CVS Insider Filing: Director-Comp Shares Planned Sale Worth $532,275

Rhea-AI Filing Summary

CVS Health Corporation: This Form 144 notifies a proposed sale of 7,500 shares of CVS common stock through Merrill Lynch on the NYSE with an aggregate market value of $532,275, scheduled approximately for 08/20/2025. The filer reports that these shares were received as director compensation across multiple grant dates between 2012 and 2022, totaling specific lots of 1,428; 2,222; 1,546; 2,099; and 205 shares. No securities were reported sold in the past three months. The notice includes the standard representation that the selling person does not possess undisclosed material adverse information.

Insights

Insider Trading Compliance Officer

TL;DR: Routine Form 144 filing for director-compensation shares; sale size appears immaterial relative to company float.

The filing reports a proposed brokered sale of 7,500 shares valued at $532,275 to occur on 08/20/2025, with the holdings acquired as director compensation over 2012–2022. From a compliance perspective, the form documents the required disclosure under Rule 144 and includes the standard attestation regarding material nonpublic information. There are no reported sales in the prior three months, and the disclosure lists the acquisition dates and amounts by lot, supporting traceability to compensatory grants.

Securities Analyst

TL;DR: Transaction is small relative to outstanding shares and is unlikely to affect CVS's market valuation.

The notice shows the proposed disposition represents 7,500 shares versus 1,267,000,000 shares outstanding, indicating a negligible dilution or market impact. The aggregate value of $532,275 is immaterial to company capitalization. The origin of the shares as director compensation is disclosed, which clarifies these are insider holdings being liquidated under Rule 144 conditions rather than broad insider divestiture. No recent sales were reported that would suggest accelerated insider selling.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch, Pierce, Fenner & Smith Incorporated 4800-4804 Deer Lake Dr. Jacksonville FL 32246	7500	532275.00	1267000000	08/20/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/07/2022	Director Compensation	CVS Health Corp			1428	11/07/2022	Director Compensation
Common	05/16/2019	Director Compensation	CVS Health Corp			2222	05/16/2019	Director Compensation
Common	05/21/2013	Director Compensation	CVS Health Corp			1546	05/21/2013	Director Compensation
Common	11/15/2012	Director Compensation	CVS Health Corp			2099	11/15/2012	Director Compensation
Common	05/10/2012	Director Compensation	CVS Health Corp			205	05/10/2012	Director Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does CVS's Form 144 filed for symbol CV S disclose?

The filing discloses a proposed sale of 7,500 shares of CVS common stock valued at $532,275 through Merrill Lynch on NYSE, dated for approximately 08/20/2025.

Were the shares being sold by a CVS insider acquired through compensation?

Yes. The filing states the shares were acquired as director compensation on multiple dates between 2012 and 2022, with individual lots listed.

Has the filer sold CVS shares in the past three months according to the Form 144?

No. The filing specifically reports "Nothing to Report" for securities sold during the past three months.

How material is the proposed sale relative to CVS outstanding shares?

Immaterial. The 7,500 shares proposed for sale are reported against 1,267,000,000 shares outstanding, indicating a negligible percentage of the float.

Which broker is handling the proposed sale of CVS shares?

Merrill Lynch, Pierce, Fenner & Smith Incorporated is named as the broker in the filing.